Director, Diagnostic Molecular Genetics Laboratory Memorial Sloan Kettering Cancer Center New York, New York, United States
Description: Participants will examine how integrated tumor-normal sequencing supports the diagnosis and treatment of solid tumors. With a focus on hereditary cancer predisposition and somatic mutation analysis, this session will highlight the clinical benefits, key limitations, and technological advances in molecular testing. Real-world implementation strategies and case studies will be shared to illustrate its growing relevance in both pediatric and adult oncology.
Learning Objectives: - Describe opportunities for and challenges of mainstreaming genetic testing for cancer patients. - Describe the advantages of using paired tumor-normal sequencing for genetic testing as compared to just using a single blood or saliva specimen for germline testing.
